FI3648788T5 - Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää - Google Patents

Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää Download PDF

Info

Publication number
FI3648788T5
FI3648788T5 FIEP18746458.1T FI18746458T FI3648788T5 FI 3648788 T5 FI3648788 T5 FI 3648788T5 FI 18746458 T FI18746458 T FI 18746458T FI 3648788 T5 FI3648788 T5 FI 3648788T5
Authority
FI
Finland
Prior art keywords
von willebrand
willebrand factor
used according
rvwf
recombinant von
Prior art date
Application number
FIEP18746458.1T
Other languages
English (en)
Finnish (fi)
Other versions
FI3648788T3 (fi
Inventor
Miranda Chapman
Bruce Ewenstein
Bettina Ploder
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of FI3648788T3 publication Critical patent/FI3648788T3/fi
Publication of FI3648788T5 publication Critical patent/FI3648788T5/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FIEP18746458.1T 2017-07-07 2018-07-09 Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää FI3648788T5 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762530027P 2017-07-07 2017-07-07
PCT/US2018/041320 WO2019010497A1 (en) 2017-07-07 2018-07-09 TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION

Publications (2)

Publication Number Publication Date
FI3648788T3 FI3648788T3 (fi) 2024-08-16
FI3648788T5 true FI3648788T5 (fi) 2024-09-09

Family

ID=63036433

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18746458.1T FI3648788T5 (fi) 2017-07-07 2018-07-09 Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää

Country Status (16)

Country Link
US (5) US10632176B2 (https=)
EP (2) EP3648788B1 (https=)
JP (2) JP7307047B2 (https=)
KR (2) KR20260037107A (https=)
CN (1) CN111436193A (https=)
AU (2) AU2018298233B2 (https=)
BR (1) BR112020000321A2 (https=)
CA (1) CA3069295A1 (https=)
CO (1) CO2020001322A2 (https=)
DK (1) DK3648788T3 (https=)
ES (1) ES2986574T3 (https=)
FI (1) FI3648788T5 (https=)
MX (1) MX2025012580A (https=)
PL (1) PL3648788T3 (https=)
PT (1) PT3648788T (https=)
WO (1) WO2019010497A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069295A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
US20220395560A1 (en) * 2019-02-01 2022-12-15 Takeda Pharmaceutical Company Limited METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
US12128090B2 (en) * 2019-02-01 2024-10-29 Takeda Pharmaceutical Company Limited Methods of prophylactic treatment using recombinant VWF (rVWF)
EP4013389A1 (en) * 2019-08-16 2022-06-22 Octapharma AG Stabilizing buffer for factor viii and vwf

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS62502589A (ja) 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CA2591852A1 (en) 2004-12-27 2006-07-06 Baxter International Inc. Polymer-von willebrand factor-conjugates
EP3653699A1 (en) 2006-01-04 2020-05-20 Baxalta Incorporated Oligopeptide-free cell culture media
ES2392569T3 (es) 2007-06-13 2012-12-11 Csl Behring Gmbh Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
CA2704234A1 (en) 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
CN105816858B (zh) 2007-12-28 2024-10-18 武田药品工业株式会社 重组vwf配方
KR101648734B1 (ko) 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 viii, 폰 빌레브란트 인자 또는 이들의 복합체
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
AU2010279463A1 (en) 2009-08-04 2012-03-01 Baxter Healthcare S.A. Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
CA2805557A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant high molecular weight vwf in cell culture
ES2682249T3 (es) * 2011-06-10 2018-09-19 Baxalta GmbH Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
CA3069295A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf

Also Published As

Publication number Publication date
JP2023123738A (ja) 2023-09-05
US12016904B2 (en) 2024-06-25
RU2020105682A3 (https=) 2021-10-15
US10632176B2 (en) 2020-04-28
CO2020001322A2 (es) 2020-02-18
AU2018298233B2 (en) 2025-04-24
RU2020105682A (ru) 2021-08-10
KR20260037107A (ko) 2026-03-17
WO2019010497A1 (en) 2019-01-10
US20230122958A1 (en) 2023-04-20
AU2025205392A1 (en) 2025-09-25
JP7641327B2 (ja) 2025-03-06
US11529395B2 (en) 2022-12-20
PL3648788T3 (pl) 2024-10-07
BR112020000321A2 (pt) 2020-07-14
CA3069295A1 (en) 2019-01-10
EP3648788A1 (en) 2020-05-13
PT3648788T (pt) 2024-08-23
US20240316160A1 (en) 2024-09-26
EP4424366A3 (en) 2024-12-04
US20200206318A1 (en) 2020-07-02
JP7307047B2 (ja) 2023-07-11
JP2020526525A (ja) 2020-08-31
US20210169989A1 (en) 2021-06-10
US10905746B2 (en) 2021-02-02
US20190091299A1 (en) 2019-03-28
CN111436193A (zh) 2020-07-21
KR20200037235A (ko) 2020-04-08
AU2018298233A1 (en) 2020-01-30
EP4424366A2 (en) 2024-09-04
DK3648788T3 (da) 2024-08-19
FI3648788T3 (fi) 2024-08-16
EP3648788B1 (en) 2024-05-22
MX2025012580A (es) 2026-01-07
ES2986574T3 (es) 2024-11-12
KR102921337B1 (ko) 2026-02-02

Similar Documents

Publication Publication Date Title
FI3648788T5 (fi) Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
ZA202211060B (en) Anti-viral compounds and methods for administration thereof
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
JP2018526460A5 (https=)
JP2016517421A5 (https=)
RU2017128296A (ru) Композиция для лечения бесплодия
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
FI3261661T3 (fi) Menotropiini hedelmättömyyden hoitamiseksi
MX389088B (es) Métodos para tratar el vhc.
JP2020531527A5 (https=)
JP2020526525A5 (https=)
JP2014530246A5 (https=)
CO2020001314A2 (es) Tratamiento de pacientes con enfermedad de von willebrand grave que se someten a cirugía electiva mediante administración de vwf recombinante
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
MX2018008443A (es) Composición farmacéutica que comprende nebivolol con tasa de disolución mejorada.
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
RU2022116119A (ru) Лечение желудочно-кишечного кровотечения у пациентов с тяжелой формой болезни фон виллебранда путем введения рекомбинантного ффв
Sharifnia et al. Effect of ephedrine on pain and hemodynamic status on injection of propofol
BR112021018219A2 (pt) Método de tratamento de endocardite infecciosa
MX2021004511A (es) Medicamento para el tratamiento y/o mejora de la septicemia asociada con la anomalia de la coagulacion.
Palacios-Zabalza Acenocoumarol/levofloxacin
EA201700347A3 (ru) Средство для эффективного купирования острого и/или хронического болевого синдрома и способ его применения
MX372644B (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
Merkulov et al. Treatment of type 1 complex regional pain syndrome in 14 years old child
AR118608A2 (es) TRATAMIENTO DE LOS TRASTORNOS DE LA COAGULACIÓN MEDIANTE LA ADMINISTRACIÓN DE UN FACTOR DE VON WILLEBRAND (vWF) RECOMBINANTE